Navigation Links
WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/14/2011

e income287,87763,381  Total stockholders' equity (deficit)(4,055,272)(1,347,936)$

5,816,565$

6,891,154Consolidated Statements of OperationsPeriod FromThree Months EndedYear EndedOctober 22, 2002(Inception) toDecember 31,December 31,December 31,20102009201020092010Revenue

$

712,369$

189,757$

2,167,289$

379,373$

3,462,796Cost of revenue278,27056,380862,066263,0411,467,006  Gross margin434,099133,3771,305,223116,3321,995,790Operating expenses:  Sales and marketing694,340149,0042,072,611601,2454,854,870  Research and development1,628,2621,700,4586,714,3405,142,08322,552,813  General and administrative1,645,0701,213,0655,097,7974,383,08216,871,033Total operating expenses3,967,6723,062,52713,884,74810,126,41044,278,716Operating loss(3,533,573)(2,929,150)(12,579,525)(10,010,078)(42,257,926)Other income and (expenses):  Interest income2,4644,70117,53614,493277,394  Interest expense(29,375)(2,375)(31,329)(9,570)(352,783)  Unrealized gain (loss) on fair value of put option, net(35,906)––88,567—88,567  Unrealized gain (loss) on fair value of warrants, net540,618(63,739)555,144(564,122)(8,978)  Miscellaneous expense(2,077)(16,727)(137,774)(51,211)(267,489)Total other income and (expenses)475,724(78,140)492,144(610,410)(263,289)Net loss before provision for income taxes(3,057,849)(3,007,290)(12,087,381)(10,620,488)(42,546,215)Provision for income taxes—————Net loss(3,057,849)(3,007,290)(12,087,381)(10,620,488)(42,546,215)Cumulative effect of reclassification of warrants————368,627Accretion on Redeemable Convertible Preference Shares in subsidiary associated with premium(63,484)(63,070)(286,948)(178,162)(503,026)Accretion on Redeemable Convertible Preference Shares in subsidiary associated with beneficial conversion feature––––(428
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors
2. WaferGen to Present at 13th Annual BIO CEO and Investor Conference
3. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
4. WaferGen to Present at OneMedForum San Francisco 2011
5. WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System
6. WaferGen Announces $7 Million Capital Raise -- $5 Million Equity Private Placement Agreement Signed, and $2 Million Credit Facility Closed
7. WaferGen Reports Second Quarter 2010 Financial Results
8. WaferGen to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System
9. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
10. Cellceutix Reports Production of Its Anti-Cancer Drug Kevetrin™ Has Begun
11. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  The Chemistry, ... Tobago Ministry of Health approved the introduction of ... increases the cure rate from Hepatitis C, and ... genotype 1 virus. Telaprevir is available in ... INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... 25, 2014  Acsis Inc., the market leader ... solutions, has recently posted an article, "Future ... and future needs for companies, extended supply chain, ... chain model no longer work today.  The article ... growth of mobile technology, machine to machine (M2M) ...
(Date:7/25/2014)... 25, 2014 According to a ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, ... Growth, Trends and Forecast (Value and Volume), 2013 - ... 19.99 billion in 2012 and is expected to grow ... to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
(Date:7/27/2014)... July 27, 2014 The European Agricultural ... in Europe with analysis and forecast of revenue. The ... from around $509.4 million in 2013 to $657.1 million ... to 2018. , Browse through the TOC of the ... of the in-depth analysis provided. It also provides a ...
(Date:7/27/2014)... 27, 2014 Metachromatic leukodystrophy (MLD, ... storage disease which is commonly listed in the ... sphingolipidoses as it affects the metabolism of sphingolipids. ... the fatty covering which acts as an insulator ... nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 One of the ... genomics products from the Asia Pacific (APAC) region. The Diagnostics ... to generate high demand for genomics solutions, thereby contributing to ... will grow at a CAGR of 11.21 percent over ... driver of the market is an increase in the demand ...
(Date:7/27/2014)... 2014 Alta Resources , a ... for Fortune 500 brands, announced today that it plans ... in Wisconsin, California, Florida and the Philippines. , A ... clients, which have seasonal ramp-ups that require additional staffing ... 2014 through February 2015. As more consumers become eligible ...
(Date:7/27/2014)... 27, 2014 Wright & Schulte LLC ... filed a GranuFlo lawsuit against Fresenius Medical Care ... over the recalled dialysis drugs GranuFlo and NaturaLyte. The ... by not disclosing the heart attack risks associated with ... Fresenius notified its own clinics, practitioners and physicians about ...
Breaking Medicine News(10 mins):Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 2Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 3Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 4Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 5Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 2Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 3Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 4Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 5
... of Chemicals, has shifted the burden or responsibility of handling ... would be bound by law to make use of only ... law aims to make chemicals used in all products ; ... ,The European Parliament has approved this legislation on ...
... plausible culprit for rendering sick nearly 260 Tewksbury students, ... stomach virus// has allegedly gripped several of the students ... not about to spare anyone- teachers, parents and siblings ... us to keep everything clean,” said Sue McLaughlin, co-chairwoman ...
... for ovarian cancer are at increased risk of a ... have high// levels of a binding protein that triggers ... of malignancy. ,“Now there’s the possibility that ... surgery might identify women most at risk for recurrence ...
... symptoms, including enlarged or painful breast tissue, but the ... Mayo Clinic Cancer Center. // Mammograms are used to ... very rare in males. ,Their study, presented Saturday, ... Antonio Breast Cancer Symposium, suggests physicians should reconsider ordering ...
... vaccine against HIV/AIDS, the 'social vaccine' of mass awareness needs ... a top UN official here said Saturday. // ... HIV/AIDS," said Peter Piot, executive director of United Nations Programme ... create a mass awareness to educate the people about the ...
... followed the discovery of neural stem cells and their potential ... spinal cord//, recent research identified “cancer stem cells,” a small ... cells comprising a malignant brain tumor. Theoretically, if these mother ... to sustain itself. On the other hand, if these cells ...
Cached Medicine News:Health News:'Clumping' Protein Linked to Return of Ovarian Cancer 2Health News:Use of Mammograms in Men 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 3
The Deluxe Knee Immobilizer provides superb lightweight immobilization following injury or surgery. It is available in a wide array of sizes for excellent comfort and fit....
... and Defiance III is DonJoy's hallmark knee ... and design, this lightweight brace provides durable ... MCL and LCL instabilities. Plus, the low-profile ... uniforms, including hockey and football. As the ...
Provides range-of-motion control for both flexion and extension along with a drop lock feature...
Dynamic brace that provides a low load, prolonged stretch to the connective tissue around the joint using an adjustment hinge with a built-in tension spring...
Medicine Products: